BACKGROUND: Our aim was to assess the correlation between the radiation therapy (RT) dose to the mastication apparatus and trismus of oropharyngeal cancer patients. METHODS: Eighty-one patients treated with RT were analyzed. The masseter, pterygoid, and temporalis muscles and the coronoid and condyl were delineated on axial CT slices. The mean dose in these structures was correlated with outcome of quality of life questionnaires. RESULTS: Fifty-six (88%) patients responded; 16% of the patients scored grade 3/4 on the Head & Neck 35 "opening mouth" question. A significant correlation was observed between dose in masseter and pterygoid muscles and trismus (p= .02). CONCLUSION: Patients treated with brachytherapy received a lower dose in masticatory muscles. A steep dose-effect relationship between mean dose in masseter muscle and pterygoid muscles and the probability of having trismus complaints was observed; with every additional 10 Gy to the pterygoid muscle, an increase of the probability of trismus of 24% was observed.
BACKGROUND: Our aim was to assess the correlation between the radiation therapy (RT) dose to the mastication apparatus and trismus of oropharyngeal cancerpatients. METHODS: Eighty-one patients treated with RT were analyzed. The masseter, pterygoid, and temporalis muscles and the coronoid and condyl were delineated on axial CT slices. The mean dose in these structures was correlated with outcome of quality of life questionnaires. RESULTS: Fifty-six (88%) patients responded; 16% of the patients scored grade 3/4 on the Head & Neck 35 "opening mouth" question. A significant correlation was observed between dose in masseter and pterygoid muscles and trismus (p= .02). CONCLUSION:Patients treated with brachytherapy received a lower dose in masticatory muscles. A steep dose-effect relationship between mean dose in masseter muscle and pterygoid muscles and the probability of having trismus complaints was observed; with every additional 10 Gy to the pterygoid muscle, an increase of the probability of trismus of 24% was observed.
Authors: Matthew J Krasin; Kristin M Wiese; Sheri L Spunt; Chia-Ho Hua; Najat Daw; Fariba Navid; Andrew M Davidoff; Lisa McGregor; Thomas E Merchant; Larry E Kun; Lola McCrarey; Kelly A Hoth; Xiaowei Yan; Xiaoping Xiong Journal: Int J Radiat Oncol Biol Phys Date: 2010-11-17 Impact factor: 7.038
Authors: Rene-Jean Bensadoun; Dorothea Riesenbeck; Peter B Lockhart; Linda S Elting; Fred K L Spijkervet; Mike T Brennan Journal: Support Care Cancer Date: 2010-03-06 Impact factor: 3.603
Authors: Primož Strojan; Katherine A Hutcheson; Avraham Eisbruch; Jonathan J Beitler; Johannes A Langendijk; Anne W M Lee; June Corry; William M Mendenhall; Robert Smee; Alessandra Rinaldo; Alfio Ferlito Journal: Cancer Treat Rev Date: 2017-07-18 Impact factor: 12.111
Authors: Shyam D Rao; Ziad H Saleh; Jeremy Setton; Moses Tam; Sean M McBride; Nadeem Riaz; Joseph O Deasy; Nancy Y Lee Journal: Acta Oncol Date: 2015-04-29 Impact factor: 4.089
Authors: Judith A E M Zecha; Judith E Raber-Durlacher; Raj G Nair; Joel B Epstein; Sharon Elad; Michael R Hamblin; Andrei Barasch; Cesar A Migliorati; Dan M J Milstein; Marie-Thérèse Genot; Liset Lansaat; Ron van der Brink; Josep Arnabat-Dominguez; Lisette van der Molen; Irene Jacobi; Judi van Diessen; Jan de Lange; Ludi E Smeele; Mark M Schubert; René-Jean Bensadoun Journal: Support Care Cancer Date: 2016-03-17 Impact factor: 3.603
Authors: Karen E Effinger; Cesar A Migliorati; Melissa M Hudson; Kevin P McMullen; Sue C Kaste; Kathy Ruble; Gregory M T Guilcher; Ami J Shah; Sharon M Castellino Journal: Support Care Cancer Date: 2014-04-30 Impact factor: 3.603